Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White Sells 201 Shares

Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White sold 201 shares of Disc Medicine stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $51.31, for a total transaction of $10,313.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

William Richard White also recently made the following trade(s):

• On Thursday, August 1st, William Richard White sold 201 shares of Disc Medicine stock. The stock was sold at an average price of $43.44, for a total value of $8,731.44.

Disc Medicine Trading Down 0.4 %

Shares of NASDAQ:IRON opened at $49.93 on Friday. The stock’s 50-day moving average price is $47.67 and its two-hundred day moving average price is $42.25. Disc Medicine, Inc. has a 12-month low of $25.60 and a 12-month high of $77.60. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -14.77 and a beta of 0.59.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.08. As a group, research analysts forecast that Disc Medicine, Inc. will post -4.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Amalgamated Bank lifted its position in shares of Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after purchasing an additional 247 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Disc Medicine in the 2nd quarter worth approximately $129,000. SG Americas Securities LLC boosted its stake in Disc Medicine by 44.2% during the 2nd quarter. SG Americas Securities LLC now owns 4,071 shares of the company’s stock valued at $183,000 after purchasing an additional 1,247 shares during the period. ProShare Advisors LLC acquired a new stake in Disc Medicine in the 1st quarter valued at approximately $211,000. Finally, Algert Global LLC acquired a new position in shares of Disc Medicine during the second quarter valued at $239,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on IRON. BMO Capital Markets reissued an “outperform” rating and issued a $70.00 price objective (up previously from $50.00) on shares of Disc Medicine in a report on Monday, June 17th. HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of Disc Medicine in a research note on Monday, September 16th. Wedbush reissued an “outperform” rating and set a $57.00 price target on shares of Disc Medicine in a research report on Friday, August 9th. Wells Fargo & Company began coverage on shares of Disc Medicine in a report on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a report on Friday, September 20th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $64.13.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.